Fish oil is one of the most purchased supplements in the world, and one of the most poorly dosed. Most people take a standard 1000mg capsule containing 300mg of combined EPA and DHA. That's roughly one-third of the minimum dose used in cardiovascular research trials and a fraction of what some high-dose studies suggest may be needed for meaningful outcomes.
The omega-3 story got more complicated — and more interesting — in recent years when researchers started separating EPA and DHA instead of treating them as interchangeable. The REDUCE-IT trial showed a dramatic cardiovascular benefit with high-dose EPA alone. The STRENGTH trial with a different omega-3 product did not. Understanding why matters if you're trying to optimize rather than just check a box.
What EPA and DHA Actually Do
Both EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long-chain omega-3 fatty acids found primarily in oily fish and algae. Despite being classified together, they have different mechanisms, different tissue distributions, and appear to have different primary benefits.
EPA (Eicosapentaenoic Acid):
- Primary cardiovascular benefits: reduces inflammation, lowers triglycerides, may stabilize arterial plaques
- Anti-inflammatory via competition with arachidonic acid for enzyme pathways
- The fatty acid featured in REDUCE-IT and most cardiovascular outcome trials
DHA (Docosahexaenoic Acid):
- More abundant in the brain and retina than in the cardiovascular system
- Structural role in cell membranes, particularly neural
- May actually raise LDL-C slightly at high doses in some people (though particle quality may improve)
- More important for cognitive function and neurodevelopment than cardiovascular outcomes specifically
Most standard fish oil capsules contain both EPA and DHA in roughly a 1.5:1 or 2:1 EPA:DHA ratio. High-EPA products (like those used in REDUCE-IT) contain predominantly EPA with minimal DHA. The distinction matters for which benefits you're prioritizing.
Related: Try our Supplement Comparison Tool to test this yourself. Also worth reading: hsCRP: The Heart Disease Inflammation Marker and our Heart & Cardiovascular Health for Men.
The Triglyceride Effect
This is the most consistent finding across omega-3 research: EPA and DHA both lower triglycerides, dose-dependently. The relationship is roughly linear:
- 1g EPA+DHA per day: ~5-10% reduction
- 2g per day: ~10-20% reduction
- 4g per day: ~20-30% reduction
For men with elevated triglycerides (above 150 mg/dL), this is often the most practically relevant effect. Omega-3s appear to reduce triglyceride synthesis in the liver and increase their breakdown.
If your triglycerides are already in the optimal range (under 80 mg/dL), the absolute effect will be smaller — you can't substantially reduce something that's already low.
REDUCE-IT: The High-Dose EPA Trial
The REDUCE-IT trial remains the most discussed omega-3 cardiovascular study. It randomized over 8,000 people with elevated triglycerides and established cardiovascular disease (or diabetes) to either 4g/day of icosapentaenoic acid ethyl ester (Vascepa, pure EPA) or a mineral oil placebo. The primary endpoint — a composite of cardiovascular events — was reduced by 25% in the EPA group over approximately five years.
This is a striking result. But three important caveats:
- The comparison group received mineral oil, which may have actually increased cardiovascular events in some analyses (making the difference appear larger than it would have against a neutral placebo)
- The participants had elevated triglycerides at baseline (150-499 mg/dL) — the benefit may be attenuated in people with normal triglycerides
- Vascepa is a prescription pharmaceutical at 4g/day — not the same as typical OTC fish oil
Why STRENGTH Differed
The STRENGTH trial used a combined EPA+DHA product (omega-3 carboxylic acids) at 4g/day versus corn oil placebo in a similar population. It was stopped early for futility — no cardiovascular benefit was observed.
Possible explanations include: the corn oil placebo may have been genuinely neutral (unlike mineral oil), the EPA:DHA ratio matters for cardiovascular outcomes, and the presence of DHA may diminish some EPA benefits. The field remains debated.
Practical Dosing Strategy
Given the evidence, here's how to think about dosing:
For general cardiovascular support and triglyceride management:
- 2-4g combined EPA+DHA daily
- Prioritize a high-EPA product (EPA:DHA ratio of 3:1 or higher)
- Triglyceride response is the most reliable short-term indicator
For anti-inflammatory effects:
- Similar dosing applies; EPA is the more relevant fatty acid
- Monitor hsCRP over 12 weeks as a response marker
For cognitive and brain health:
- DHA becomes more relevant here
- A balanced EPA:DHA product (2:1 or 1:1) may be more appropriate
Pros
- +Triglyceride reduction is consistent and dose-dependent across studies
- +Anti-inflammatory effects are mechanistically well-supported
- +High-EPA formulations have the strongest cardiovascular outcome trial data
- +Safe at standard doses with decades of research
- +Algae-based options provide the same EPA and DHA without concerns about fish sourcing or oxidation
Cons
- -Most OTC fish oil is underdosed for meaningful cardiovascular effects
- -Fish oil oxidizes easily — product quality varies widely and rancid oil may be harmful
- -DHA may modestly raise LDL-C in some people at high doses
- -High doses (4g/day) carry a slightly elevated bleeding risk at the margins
- -REDUCE-IT results may not generalize to people with normal triglycerides
Product Quality Matters More Than Most People Realize
Omega-3 supplements degrade rapidly when exposed to oxygen, light, and heat. Rancid fish oil is not just less effective — there's some evidence oxidized lipids may have negative effects. Markers to evaluate:
- TOTOX value (measure of oxidation): Should be under 10
- Third-party testing: IFOS (International Fish Oil Standards) certification is the clearest marker of quality
- Smell test: A strong fishy smell suggests oxidation. Mild fishy is normal; pungent is not
Store in the refrigerator after opening and don't buy products sitting in warm retail environments.
How to Track Whether It's Working
Triglycerides are the most responsive and easy-to-measure marker. Retest after 8-12 weeks of consistent dosing. A meaningful triglyceride reduction (20%+ from elevated baseline) is a reliable indicator the protocol is working.
hsCRP — high-sensitivity C-reactive protein — reflects the anti-inflammatory effects. Retest at 12 weeks.
Omega-3 index — a red blood cell measurement of EPA+DHA content — reflects actual tissue incorporation. An omega-3 index above 8% is associated with favorable cardiovascular outcomes in observational data. This is available through specialty labs.
Be the first to try Prova
We're building an app to track whether omega-3-tracking actually works. Join the waitlist.
The Bottom Line
Omega-3s are worth taking seriously, but dose and form matter significantly. The standard 1g fish oil capsule is largely ceremonial for cardiovascular effects — meaningful cardiovascular support likely requires 2-4g EPA+DHA daily, with a preference for high-EPA formulations based on the available outcome data. Triglycerides are your easiest feedback mechanism. Test before, stay consistent for 12 weeks, and let the numbers guide whether the protocol is actually doing anything for your specific physiology.